

INDEX

Numbers in *italics* refer to pages on which tables appear. Numbers in **boldface** refer to pages on which images appear.

A

- acetic acid-zinc-formalin
 - fixation time and implications, 4
 - sample results, **7–10**
 - turnaround time and diagnostic implications, 6
- acids, decalcification applications, 5
- actin
 - association with adipocytes, **217**
 - association with dendritic cells, **217**
 - association with stromal cells, **217** in non-Hodgkin lymphoma staging, in endosteal lining cells, and in classical Hodgkin lymphoma sample, **218**
- actin smooth muscle, in pericytes; contrasted with desmin **217, 218**
- activated lymphocytes, CD25 in, **77**
- activated T cells
 - CD3 in, **18**
 - CD5 in, **28**
- acute bilineal leukemia
 - acute leukemia diagnostic considerations with CD34, myeloperoxidase, CD20, CD3, TdT, von Willebrand factor, and CD117, **246**
 - terminal deoxynucleotidyltransferase (TdT) in, **172**
- acute biphenotypic leukemia
 - acute leukemia diagnostic considerations with CD34, myeloperoxidase, CD20, CD3, TdT, von Willebrand factor, and CD118, **246**
 - CD3 in, **19**
 - CD117 in, **129**
 - terminal deoxynucleotidyltransferase (TdT) in, **171**
- acute erythroid leukemia
 - acute leukemia diagnostic considerations with epithelial membrane antigen, **243**
 - CD15 in, **53**
 - CD117 in, **131**
 - CD138 in, **138**
 - CD235a in, **141**
 - Fli-1 in, **193**
 - glycophorin A expression, **141**
 - hemoglobin A in, **160**
 - lysozyme vs myeloperoxidase in, **200**
 - myeloperoxidase vs lysozyme in, **200**
 - Pax-5 in, **181**
 - vimentin in, **215**
- acute hypocellular leukemia, myeloperoxidase in, **155**
- acute leukemia, undifferentiated
 - acute leukemia diagnostic considerations with CD2 negativity, **244**
 - acute leukemia diagnostic considerations with Ki-67, **245**
 - CD4 in, **56**
 - CD16 in, **56**
 - CD16 in, **57**
 - CD68 vs CD16 in, **57**
 - PU.1 in, **187**
 - terminal deoxynucleotidyltransferase (TdT) in, **173**
- acute leukemias
 - diagnostic considerations, 237–246
 - flow cytometry diagnostic role, 3
 - recommended panels, 253
- acute lymphoblastic leukemia
 - CD10 in, **41**
 - CD15 in, **53**
 - CD34 14 days after chemotherapy, **93**
 - myeloperoxidase in, **157**
 - terminal deoxynucleotidyltransferase (TdT) in, **168**
- acute megakaryoblastic leukemia
 - acute leukemia diagnostic considerations with CD20, **244**
 - acute leukemia diagnostic considerations with CD34, **240**
 - acute leukemia diagnostic considerations with vimentin **243**
 - CD31 in, **83**
 - CD61 in, **110, 112**
 - von Willebrand factor in, **177, 178**
- acute monoblastic leukemia
 - CD33 in, **87**
 - CD45RA in, **101**
 - CD99 in, **124**
 - myeloperoxidase expression in, **87**
- acute monocytic leukemia, acute leukemia diagnostic considerations with myeloperoxidase, **238**
- acute myeloid leukemia
 - acute leukemia diagnostic considerations with CD34 and CD45, **240**
 - acute leukemia diagnostic considerations with CD79a, **244**
 - acute leukemia diagnostic considerations with CD117, **239**
 - acute leukemia diagnostic considerations with hemoglobin **241**
 - acute leukemia diagnostic considerations with Ki-67, CD23, **245**
 - acute leukemia diagnostic considerations with TdT, CD123, **242**
 - acute leukemia diagnostic considerations with vimentin **243**
 - biopsy sample with AZF fixative, **8**
 - CD15 in, **53**
 - CD31 in, **83**
 - CD34 in, **89, 90, 92**
 - CD34 in, 14 days after chemotherapy, **93**
 - CD45RO in, **103**
 - CD56 in, **107**
 - CD61 in, **112**
 - CD117 in, **129, 130, 131**
 - CD117 in after chemotherapy, **94, 132**
 - CD138 in, **135, 138**
 - CD235a in, **141**
 - false negatives with myeloperoxidase, **155**
 - Fli-1 in, **193**
 - glycophorin A expression, **141**
 - hemoglobin A in, **160**
 - immunoglobulins in, **208**
 - lysozyme vs myeloperoxidase in, **200**
 - myeloperoxidase in, **156**
 - myeloperoxidase vs CD15 in, **155**
 - myeloperoxidase vs lysozyme in, **200**
 - Pax-5 in, **182**
 - PU.1 in, **187, 188**
 - terminal deoxynucleotidyltransferase (TdT) in, **171, 172**
 - vimentin in, **215**

- acute myeloid leukemia, undifferentiated, CD10 stromal induction in, **42**
- acute myelomonoblastic leukemia
 CD31 in, **82, 83**
 CD99 in, **125**
 CD117 in, **130**
- acute myelomonocytic leukemia
 acute leukemia diagnostic considerations with CD117, myeloperoxidase, PG-M1, lysozyme, and KP-1, **239**
 acute leukemia diagnostic considerations with myeloperoxidase, **238**
 acute leukemia diagnostic considerations with TdT, **241**
 CD34 in, **92**
 terminal deoxynucleotidyltransferase (TdT) in, **173**
- acute panmyelosis with myelofibrosis, CD61 in, **111**
- acute promyelocytic leukemia
 biopsy sample with AZF fixative, **7**
 CD3 in, **21**
 CD14 in, **48, 50**
 CD68 vs CD14 in, **50**
 CD117 in, **130**
 terminal deoxynucleotidyltransferase (TdT) in, **172**
 von Willebrand factor in, **176**
- acute undifferentiated leukemia, acute leukemia diagnostic considerations with myeloperoxidase, **238**
- adenocarcinoma
 CD3 in metastatic, **19**
 metastatic tumor diagnostic considerations, **248**
- adenocarcinoma of the stomach, CD20 in, **61**
- adipocytes
 actin association with, **217**
 CD10 in, **38**
 CD25 in, **76**
 Cyclin D1 in, **195**
 EnVision CD10 sensitivity, **39**
 S-100 protein in, **219**
 TdT+ cell associational with, **168**
- AE1
 acute leukemia diagnostic considerations with acute myeloid leukemia, **243**
 metastatic tumor diagnostic considerations, **248**
- AE3
 acute leukemia diagnostic considerations with acute myeloid leukemia, **243**
 metastatic tumor diagnostic considerations, **248**
- alcohol, tissue processing considerations, **4**
- ALK-1, recommended panel applications, **253**
- AML. See acute myeloid leukemia.
- anemia, von Willebrand factor in, **175**
- anemia, aplastic, CD14 in, **47**
- angioimmunoblastic T-cell lymphoma, Bcl-6 in, **202**
- antigen diffusion, with CD15, **52**
- antigen retrieval, methods and recommendations, **5–6**
- APL. See acute promyelocytic leukemia.
- aplastic anemia
 CD14 in, **47**
 hemoglobin A in, **160**
- APMF (acute panmyelosis with myelofibrosis), CD61 in, **111**
- artifacts, analytical, diagnostic implications, **1**
- atypical lymphoid aggregates, Cyclin D1 in, **196**
- AZF (acetic acid-zinc-formalin)
 fixation time and implications, **4**
 sample results, **7–10**
 turnaround time and diagnostic implications, **6**
- B**
- B cells, vimentin in, **215**
- B1, **57–63**
- B1 thymoma and myasthenia gravis, CD1a in, **14**
- B5 fixative, fixation time and implications, **4**
- B6, **69–74**
- B72.3
 localization in diagnosis, **2**
 metastatic tumor diagnostic considerations, **250**
- B220, **97–103**
- bands, CD16 in, **55**
- B-cell leukemia/lymphoma 2 (Bcl-2), **226–228**
- B-cell lymphoma
 CD5 expression interpretation, **28–29**
 interpretation with CD5 and CD3, **28–29**
 mature, Pax-5 highlighting of intrasinusoidal distribution, **184**
 mature, Pax-5 vs CD20 in, **183**
- B-cell lymphoma-6, **201–203**
- B-cell neoplasms, recommended panels, **253**
- B-cell precursor, CD22 and CD10 in, **69**
- B-cell-specific activator protein, **178–185**
- Bcl-1, **194–199**
- Bcl-2, **226–228**
 in blasts, **227**
 in chronic myelomonocytic leukemia, **228**
 localization in diagnosis, **2**
 in myeloid precursors, **227**
 in normal bone marrow, **226, 227**
 in precursor B-cell lymphoblastic leukemia, **228**
 in promyelocytes, **227**
 recommended panel applications, **253**
 in small B-cell lymphoproliferative diseases, **227**
- Bcl-3, recommended panel applications, **253**
- Bcl-6, **201–203**
 in angioimmunoblastic T-cell lymphoma, **202**
 biopsy sample with AZF fixative, **10**
 in diffuse large B-cell lymphoma, **202–203**
 in endothelial cells, **201**
 in follicular lymphoma, **202**
 localization in diagnosis, **2**
 in marginal zone lymphoma, **201**
 in monocytic cells, **201**
 in normal bone marrow, **201**
 in peripheral T-cell lymphoma, **202**
 in perivascular monocytic cells, **202**
 recommended panel applications, **253**
- benign lymphoid aggregate, CD4 in, **25**
- benign mast cells, CD33 in, **86**
- benign plasma cells, CD99 in, **126**
- benign T cells
 CD5 in with hairy cell leukemia, **30**
 infiltrating lymphoplasmacytic lymphoma, CD3 in, **23**
 infiltrating mantle cell lymphoma, CD3 in, **24**
- BER-EP4, metastatic tumor diagnostic considerations, **248**
- Ber-H2 antigen, **78–81**

- biphenotypic leukemia, acute,
 CD3 in, **19**
 CD15 in, **53**
- BLAST-2, 69–74
- blasts, Bcl-2 in, **227**
- B-lymphoid cells, interstitial infiltration example, **9**
- BOB1
 biopsy sample with AZF fixative, **10**
 localization in diagnosis, **2**
 recommended panel applications, **253**
- bone marrow, hypoplastic, hemoglobin A in, **160**
- bone marrow, reactive, mast cell tryptase in, **162**
- bone marrow sinusoids, megakaryocyte-endothelial cell association, **177**
- Bouin fixative, fixation time and implications, **4**
- Bp35, 57–63
- breast carcinoma, metastatic tumor diagnostic considerations, **250, 252**
- BSAP (B-cell-specific activator protein), 178–185
- buffered formal-saline, fixation time and implications, **4**
- C**
- C3bR, 95–97
- C4bR, 95–97
- CA-125
 localization in diagnosis, **2**
 metastatic tumor diagnostic considerations, **252**
- calcium chelator EDTA
 decalcification applications, **5**
 decalcification time and processing implications, **5**
 turnaround time and diagnostic implications, **6**
- CD nomenclature, **13**
- CD1a, 13–15
 in B1 thymoma and myasthenia gravis, **14**
 in Langerhans cell histiocytosis, **14, 15**
 in precursor T-cell acute lymphoblastic leukemia, **14**
 recommended panel applications, **253**
 in thrombocytopenia with no definite bone pathology, **13**
- CD2, 16–17
 acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 recommended panel applications, **253**
- CD2R, 16–17
- CD3, 17–24
 in activated T cells, **18**
 acute leukemia diagnostic considerations with acute bilineal leukemia, **246**
 in acute promyelocytic leukemia, **21**
 in adenocarcinoma, metastatic, **19**
 in atypical lymphoid aggregate, **22**
 in atypical T cells, nonmalignant, **20**
 in benign T cells infiltrating lymphoplasmacytic lymphoma, **23**
 in benign T cells infiltrating mantle cell lymphoma, **24**
 biopsy sample with AZF fixative, **10**
 in biphenotypic leukemia, acute, **19**
 in CD5 expression interpretation, **28**
 in chronic myeloid leukemia, **23**
 in classical Hodgkin lymphoma, **20**
 in CML (chronic myeloid leukemia), **23**
 vs cytotoxic markers in T-cell large granular lymphocytic leukemia, **213**
 in follicular lymphoma, **18, 19**
 in HIV+ patient with atypical lymphoid aggregate, **22**
 in hypocellular bone marrow with increased hematogones, **22**
 in interstitial lymphoid aggregates, **22**
 in lymphoplasmacytic lymphoma infiltrated by benign T cells, **23**
 in multiple myeloma, **18**
 in myelogenous leukemia, after induction chemotherapy, **18**
 in nodal diffuse large B-cell lymphoma, **22**
 in normal bone marrow, **17**
 in peripheral T-cell lymphoma, **21**
 in perivascular T cells, **20**
 in precursor T-lymphoblastic leukemia, **23**
 in peripheral T-cell lymphoma, **21**
 in reactive T cells, **18, 19**
 recommended panel applications, **253**
- CD4, 24–26
 in benign lymphoid aggregate, **25**
 in epithelioid histiocytes, **26**
 in hemophagocytic histiocytes, **26**
 recommended panel applications, **253**
 in sinusoidal endothelial cells, **25**
 in T lymphocytes in normal bone marrow, **25**
- CD5, 27–30
 in activated T cells, **28**
 in B-cell lymphoma, interpretation of, **28–29**
 in benign T cells, **30**
 biopsy sample with AZF fixative, **9**
 cytoplasmic and membranous expression of, **28**
 in diffuse large B-cell lymphoma, **30**
 in follicular lymphoma, **30**
 in hairy cell leukemia, **30**
 in hemophagocytic syndrome, **30**
 in histologically normal bone marrow, **27**
 in mantle cell lymphoma, **29**
 membranous and cytoplasmic expression of, **28**
 in peripheral T-cell lymphoma, **29–30**
 recommended panel applications, **253**
- CD7, 31–32
 in peripheral T-cell lymphoma, **32**
 in reactive T cells, **31**
 recommended panel applications, **253**
 in refractory anemia with excess blasts, **31**
- CD8, 32–35
 in classical Hodgkin lymphoma staging, **34**
 in endosteal lining cells, **34**
 in endothelial cells, **33**
 Golgi-type expression, **35**
 in histologically normal bone marrow, **33**
 in interstitial T cells, **33**
 lymphocytosis, **35**
 membranous expression, **35**
 in normal bone marrow, **33**
 peripheral T-cell lymphoma, **35**
 recommended panel applications, **253**
 refractory anemia with excess blasts, **35**
 in T cells, interstitial, **33**
 T-cell large granular lymphocytic leukemia, **35**

- CD9, 36–38
 in endothelial cells, **37**
 in lymphoid cells, small, **37**
 in mast cells, **37**
 in pericytes, **36, 37**
 in perivascular plasma cells, **37**
 in plasma cells, **37**
 in platelets, **36**
 in stromal bone marrow cells, **38**
 in vascular smooth muscle, **36**
- CD10, 38–44
 in acute lymphoblastic leukemia, **41**
 in adipocytes, **38**
 vs CD68 (via PG-M1) in precursor B-cell lymphoblastic leukemia, **117**
 in dendritic stromal cells, **43**
 in double-stained specimen with CD22, **69**
 in endosteal lining cells, **44**
 EnVision sensitivity, **39**
 in follicular lymphoma, **43, 44**
 in hematogones, **41**
 in lymphoid cells, immature, **38**
 in maturing lymphocytes, **39**
 in neoplastic lymphoid aggregates, **41**
 in neutrophils, **38, 39, 40**
 in plasma cells, **41**
 in precursor B-cell lymphoblastic leukemia, **40**
 recommended panel applications, **253**
 in stromal cell dendritic extensions, **38**
 stromal induction in various neoplasms, **42**
- CD14, 44–50
 in acute promyelocytic leukemia, **48**
 in chronic myeloid leukemia, **50**
 in chronic myelomonocytic leukemia, **48**
 in circulating monocytes, **46**
 in classical Hodgkin lymphoma, **45**
 cytoplasmic ruffles with, **45**
 in dendritic cells, **48**
 in endothelial cells, **46**
 in hemophagocytic syndrome, **48, 49**
 in histologically normal bone marrow, **45, 46**
 in interstitium, **45**
 in macrophages, **48**
 in macrophages, **45, 46**
 in monocytes, **45**
 in normal bone marrow, **45, 46**
 in peripheral T-cell lymphoma, **48, 49**
 in promyelocytic leukemia, acute, **48**
 in stromal dendritic cells, **45, 46**
- CD15, 51–53
 in acute erythroid leukemia, **53**
 in acute lymphoblastic leukemia, **53**
 in acute myeloid leukemia, **53**
 in antigen diffusion, **52**
 in biphenotypic leukemia, acute, **53**
 in classical Hodgkin lymphoma, **52**
 in dendritic cells, **52**
 in erythroid hyperplasia, **51**
 in histiocytic cells, **52**
 in histologically normal bone marrow, **51**
 metastatic tumor diagnostic considerations, **249**
 CD15, vs myeloperoxidase in acute myeloid leukemia, **155**
 in normal bone marrow, **51**
 recommended panel applications, **253**
- CD16, 54–56
 in bands, **55**
 in dendritic cells, **56**
 in histologically normal bone marrow, **54–55**
 in macrophages, **56**
 in macrophages, **57**
 in metamyelocytes, **55**
 in segmented neutrophils, **55**
 in stromal cells, **56**
 in undifferentiated acute leukemia, **56**
 in undifferentiated acute leukemia, **57**
- CD19, acute leukemia diagnostic considerations with acute megakaryoblastic leukemia, **244**
- CD20, 57–63
 acute leukemia diagnostic considerations with acute bilineal leukemia, **246**
 acute leukemia diagnostic considerations with acute megakaryoblastic leukemia, **244**
 in adenocarcinoma of the stomach, **61**
 biopsy sample with AZF fixative, **9**
 biopsy sample with AZF fixative, **10**
 in bone marrow with Pax-5+ cells in linear arrangements, **180**
 vs CD79a in hairy cell leukemia, **122**
 vs CD79a in lymphoplasmacytic lymphoma, **122**
 in chronic myeloid leukemia, **23**
 in CML (chronic myeloid leukemia), **23**
 in crushed bone marrow specimen, **63**
 cytoplasmic ruffles with, **59**
 in diffuse large B-cell lymphoma, **63**
 in fibrotic bone marrow specimen, **63**
 in follicular lymphoma, **60, 61**
 in interstitial lymphoid aggregates, **22**
 in large lymphoid aggregates, **60**
 in lymphoid aggregates, large, **63**
 in lymphoid aggregates, very small, **61**
 in lymphoplasmacytic lymphoma, **62**
 in mantle cell lymphoma, **60, 61**
 in marginal zone lymphoma, **62**
 in myeloproliferative disease, **63**
 in nodal classical Hodgkin lymphoma, **58**
 in nodal diffuse large B-cell lymphoma, **22**
 in nodular lymphocyte predominance Hodgkin lymphoma, **58**
 in normal bone marrow, **58, 59**
 vs Pax-5 in follicular lymphoma, **183**
 in precursor B-cell lymphoblastic leukemia, **63**
 in reactive bone marrow, **59**
 recommended panel applications, **253**
 in systemic lupus erythematosus, **59**
- CD21, 64–67
 vs CD35 demonstration of follicular dendritic cells, **96**
 in follicular lymphoma, **66, 67**
 in marginal zone lymphoma, **66, 67**
 in mononuclear bone marrow cell, **65**
 in normal bone marrow, **64, 65**
 in reactive lymphoid aggregate, **65**
 recommended panel applications, **253**
- CD22, 68–69
 in B-cell precursor, **69**
 in bone marrow with mild reactive changes, **68**
 in cytoplasmic and membranous expression, **69**
 in hematogones, **68**

- CD23, 69–74
 acute leukemia diagnostic considerations with acute myeloid leukemia, **245**
 vs CD35 demonstration of follicular dendritic cells, **96**
 in chronic lymphocytic leukemia, **72–74**
 in follicular dendritic cells, **70**
 in follicular lymphoma, **71**
 in hairy cell leukemia, **72**
 in interstitial chronic lymphocytic leukemia, **73, 74**
 in interstitium, **70**
 in lymphoid aggregates, reactive, **70**
 in lymphoid clusters, **74**
 in marginal zone lymphoma, **71**
 in normal bone marrow, **70**
 in normochromic normocytic anemia, **71**
 recommended panel applications, **253**
- CD25, 75–77
 in activated lymphocytes, **77**
 in adipocytes, **76**
 histologically normal bone marrow, **75**
 in mastocytosis, **76**
 normal bone marrow, **75**
 recommended panel applications, **253**
 in systemic mastocytosis, **77**
- CD30, 78–81
 biopsy sample with AZF fixative, **10**
 in classical Hodgkin lymphoma, **80**
 Golgi-type expression in cHL, **80**
 in marginal zone lymphoma, **81**
 in myeloproliferative disease, **79**
 in normal bone marrow, **78–79**
 recommended panel applications, **253**
- CD31, 81–84
 in acute megakaryoblastic leukemia, **84**
 in acute myeloid leukemia, **84**
 in acute myelomonoblastic leukemia, **82, 83**
 CD61 expression contrasted, **110**
 in normal bone marrow, **81–82**
 in precursor B-cell lymphoblastic leukemia, **84**
 recommended panel applications, **253**
 vs von Willebrand factor in myelodysplastic syndrome, **82**
- CD33, 84–87
 in acute monoblastic leukemia, **87**
 in benign mast cells, **86**
 in intestinal myeloid sarcoma, **87**
 in mast cell disease, **87**
 in normal bone marrow, **85–86**
 recommended panel applications, **253**
- CD34, 88–95
 acute leukemia diagnostic considerations with acute bilineal and biphenotypic leukemias, **246**
 acute leukemia diagnostic considerations with acute myeloid and megakaryoblastic leukemias, **240**
 acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 in acute lymphoblastic leukemia 14 days after chemotherapy, **93**
 in acute myeloid leukemia, **89**
 in acute myeloid leukemia 14 days after chemotherapy, **93**
 in acute myelomonocytic leukemia, **92**
 biopsy sample with AZF fixative, **7**
 in chronic lymphocytic leukemia, **94**
 in chronic myeloid leukemia, **89**
 in chronic myelomonocytic leukemia, **94**
 in clotted blood, **90, 91**
 in endothelial cells in direct contact with CD22+ cells, **69**
 in endothelial cells, with mantle cell lymphoma, **94**
 in hyperblastic bone marrow, **90**
 in hypocellular acute myeloid leukemia, **91**
 in hypocellular bone marrow with increased hematogones, **22**
 in lymphoid aggregates, with mantle cell lymphoma, **94**
 vs lysozyme, myeloperoxidase, and CD117 in acute myeloid leukemia, **200**
 in mantle cell lymphoma, **94**
 in megakaryocytes, **89**
 in megakaryocytes, **95**
 in normal bone marrow, **88**
 in precursor B-cell acute lymphoblastic leukemia 14 days after induction chemotherapy, **92**
 in precursor B-cell acute lymphoblastic leukemia, **91**
 recommended panel applications, **253**
 recommended panel applications, **253**
 in refractory anemia with excess blasts, **88**
 in serous atrophy, **93**
 vs VCAM-1 expression in endothelial cells, **220**
- CD35, 95–97
 in erythroid precursors, **97**
 in follicular colonization of benign interstitial aggregates, **96**
 in follicular dendritic cells, vs CD21 and CD23, **96**
 in follicular dendritic cells, with lymphoplasmacytic lymphoma, **97**
 in follicular lymphoma, **96**
 in interstitial aggregates colonized by follicular lymphoma, **96**
 in lymphoplasmacytic lymphoma, **97**
 in normal bone marrow, **95**
 recommended panel applications, **253**
- CD38
 acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 biopsy sample with AZF fixative, **8**
- CD42b, 109, 113
 in normal bone marrow, **113**
 in platelets, **113**
 recommended panel applications, **253**
- CD43, acute leukemia diagnostic considerations, **242**
- CD45
 acute leukemia diagnostic considerations with acute myeloid leukemia, **240**
 acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 biopsy sample with AZF fixative, **10**
 recommended panel applications, **253**
- CD45RA, 97–103
 in acute monoblastic leukemia, **101**
 in classical Hodgkin lymphoma, **99**
 in IgA multiple myeloma, **100**
 in IgM+ myeloma, **100**
 in lymphoplasmacytic lymphoma, **101**
 in myelomonocytic leukemia, **100**
 in normal bone marrow, **98–99**
 in precursor B-cell acute lymphoblastic leukemia, **101**
 in transformed essential thrombocythemia, **99**

- CD45RO, 102–103
 in acute myeloid leukemia, **103**
 membranous expression in peripheral T-cell lymphoma, **103**
 in myeloid cells, **103**
 in peripheral T-cell lymphoma, **102**
 in plasma cells, **103**
 recommended panel applications, 253
- CD56, 104–107
 in acute myeloid leukemia, **107**
 in benign plasma cells, **105**
 contrasted with CD57 on endosteal lining cells, **108**
 in endosteal localization, **106**
 in hematodermic neoplasm, **106**
 in lymphoid cells, **105**
 metastatic tumor diagnostic considerations, **249**
 in monoclonal gammopathy, **105**
 in natural killer cells, **105**
 in neoplastic plasma cells, **106**
 in normal bone marrow, **104**
 in paratrabeular localization, **106, 107**
 in plasmacytoid dendritic cells, **106**
 recommended panel applications, 253
 in stromal dendritic cells, **106, 107**
- CD57, 107–109
 in chronic normochromic normocytic anemia, **108**
 in classical Hodgkin lymphoma, **107–108**
 contrasted with CD56 on endosteal lining cells, **108**
 in hypocellular bone marrow, **108**
 in normal bone marrow, **107–108**
 in peripheral T-cell lymphoma, **108–109**
 recommended panel applications, 253
 in T-cell large granular lymphocytic leukemia, **109**
- CD61, 109–113
 in acute megakaryoblastic leukemia, **110, 112**
 in acute myeloid leukemia, **112**
 in acute panmyelosis with myelofibrosis, **111**
 CD31 expression contrasted, **110**
 in chronic idiopathic myelofibrosis, **113**
 cytoplasmic expression of, **110**
 dysplastic megakaryocytes expressing, **112**
 in endothelial cells, **110**
 in histologically normal bone marrow, **110**
 in megakaryoblasts, **110, 111, 112**
 membranous expression of, **110, 111**
 in myelodysplastic syndrome, **110, 111**
 in normal bone marrow, **110**
 in platelets, **110**
 recommended panel applications, 253
 in refractory anemia with excess blasts, **111**
 in systemic mastocytosis, **111**
 in trilinear dyshematopoiesis associated with myelodysplastic syndrome and acute panmyelosis, **111**
 von Willebrand factor expression contrasted, **110**
- CD68, 114–118
 biopsy sample with AZF fixative, **8**
 vs CD14 in acute promyelocytic leukemia, **50**
 in chronic myeloid leukemia, **116**
 in chronic myelomonocytic leukemia, **116**
 in hemophagocytic syndrome, **117, 118**
 localization in diagnosis, 2
 in marginal zone lymphoma, **115**
 in normal bone marrow, **114, 115**
 in peripheral T-cell lymphoma, **117**
 in precursor B-cell lymphoblastic leukemia, **116, 117**
 recommended panel applications, 253
- CD72, recommended panel applications, 253
- CD79a, 119–123
 acute leukemia diagnostic considerations with acute megakaryoblastic leukemia, **244**
 acute leukemia diagnostic considerations with acute myeloid leukemia, **244**
 biopsy sample with AZF fixative, **10**
 in classical Hodgkin lymphoma, **119**
 in focally hypocellular bone marrow, **120**
 in follicular lymphoma, **120, 121**
 in hairy cell leukemia, **122**
 in hematogones, **120, 121**
 in hypocellular bone marrow, **120**
 intrasinusoidal localization of, **121**
 in lymphoplasmacytic lymphoma, **122**
 paratrabeular localization of, **120**
 in plasma cell myeloma, **121**
 in plasma cells, **120**
 in precursor B-cell lymphoblastic leukemia, **122, 123**
 in pure erythroid acute leukemia, **123**
 in reactive bone marrow, **119**
 recommended panel applications, 253
 reliability after rituximab therapy, **180**
 vs terminal deoxynucleotidyltransferase (TdT) in showing maturational rows of hematogones, **168**
- CD99, 123–127
 acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 in acute monoblastic leukemia, **124**
 in acute myelomonoblastic leukemia, **125**
 in endothelial cells, **125**
 in hematopoietic precursor cells, **125**
 in megakaryocytes, **126**
 in multiple myeloma, **126**
 in myeloid leukemias, **125**
 negativity in erythroid precursors, **127**
 negativity in mature granulocytes, **127**
 in nodular sclerosis Hodgkin lymphoma, **126**
 in normal bone marrow, **124**
 in osteoblasts, **125**
 in osteosarcoma, **125**
 in pancytopenia, **125**
 in plasma cells, **126**
 in precursor B-cell lymphoblastic leukemia, **127**
 recommended panel applications, 253
 in sinusoidal endothelial cells, **125**
 in stromal cells, **127**

- CD99R, 123–127
- CD117, 128–133
- in acute biphenotypic leukemia, **129**
 - in acute erythroid leukemia, **131**
 - acute leukemia diagnostic considerations with acute bilineal and biphenotypic leukemias, **246**
 - acute leukemia diagnostic considerations with acute myelogenous and myelomonocytic leukemias, **239**
 - in acute myeloid leukemia, **129, 130, 131**
 - in acute myeloid leukemia, after chemotherapy, 94, **132**
 - in acute myelomonoblastic leukemia, **130**
 - in acute promyelocytic leukemia, **130**
 - biopsy sample with AZF fixative, **7**
 - in chronic myeloid leukemia, **131**
 - in hypocellular acute myeloid leukemia, **132**
 - in indolent systemic mastocytosis, **132**
 - vs lysozyme, myeloperoxidase, and CD34 in acute myeloid leukemia, **200**
 - in myeloproliferative disease, **133**
 - in normal bone marrow, **128**
 - in pancytopenia, **131**
 - paratrabecular localization after chemotherapy, **132**
 - in polycythemia vera, **133**
 - in precursor B-cell lymphoblastic leukemia, **129**
 - in reactive bone marrow, **129**
 - recommended panel applications, 253
- CD123, 133–134
- acute leukemia diagnostic considerations with acute myeloid leukemia, **242**
 - in classical Hodgkin lymphoma, **133**
 - in hairy cell leukemia, **134**
 - in normal bone marrow, **133–134**
 - recommended panel applications, 253
- CD138, 134–139
- in acute erythroid leukemia, **138**
 - in acute myeloid leukemia, 135, **138**
 - vs CD79a in follicular lymphoma, **120**
 - in chronic myelomonocytic leukemia, **139**
 - in diffuse large B-cell lymphoma, **139**
 - in IgA myeloma, **135**
 - in lymphoplasmacytic lymphoma, **139**
 - in marginal zone lymphoma, **139**
 - in multiple myeloma, **136, 137**
 - in normal bone marrow, **135**
 - in paratrabecular localization, **138**
 - perivascular distribution of, **135**
 - in plasma cells, **135**
 - in reactive plasma cells, **135**
 - recommended panel applications, 253
 - in stromal cells, **138**
- CD163
- biopsy sample with AZF fixative, **8**
 - localization in diagnosis, **2**
 - recommended panel applications, 253
- CD235a, 140–141
- in acute erythroid leukemia, **141**
 - acute leukemia diagnostic considerations with erythroleukemia, **241**
 - in acute myeloid leukemia, **141**
 - in erythroid precursors, **140**
 - in myelodysplastic syndrome, **140, 141**
- chain restriction, demonstrating monoclonality after plasma cell transplantation, **138**
- chemical reaction, in biopsy fixation, **4**
- cHL: See classical Hodgkin lymphoma.
- chromogranin
- localization in diagnosis, **2**
 - metastatic tumor diagnostic considerations, **248, 250**
- chronic idiopathic myelofibrosis, CD61 in, **113**
- chronic lymphocytic leukemia
- biopsy sample with AZF fixative, **8, 9**
 - CD23 in, **72–74**
 - CD34 in, **94**
 - Cyclin D1 in, **197**
- chronic myelogenous leukemia: See chronic myeloid leukemia.
- chronic myeloid leukemia
- acute leukemia diagnostic considerations with pancytokeratin **243**
 - CD3 in, **23**
 - CD14 in, **50**
 - CD20 in, **23**
 - CD34 in, **89, 90**
 - CD68 (via KP-1) in, **116**
 - CD68 (via PG-M1) in, **116**
 - CD117 in, **131**
 - mast cell tryptase in, **165–166**
 - myeloperoxidase in, **153**
 - myeloperoxidase in, **154**
 - PU.1 in, **190**
- chronic myelomonocytic leukemia
- Bcl-2 in, **228**
 - biopsy sample with AZF fixative, **8**
 - CD14 in, **48**
 - CD34 in, **94**
 - CD68 (via KP-1) in, **116**
 - CD68 (via PG-M1) in, **116**
 - CD138 in, **139**
 - immunoglobulins in, **208**
 - lysozyme vs myeloperoxidase in, **200**
 - mast cell tryptase in, **166**
 - myeloperoxidase in, **154**
 - myeloperoxidase vs lysozyme in, **200**
 - Pax-5 in, **179**
 - PU.1 in, **189**
- chronic normochromic normocytic anemia, CD57 in, **108**
- CIMF (chronic idiopathic myelofibrosis), CD61 in, **113**
- circulating monocytes, CD14 in, **46**
- CK7, metastatic tumor diagnostic considerations, **249**
- c-KIT, 128–133

- CLA (common leukocyte antigen), 97–103
- classical Hodgkin lymphoma
- actin presence in sample, **218**
 - biopsy sample with AZF fixative, **10**
 - CD3 in, **20**
 - CD10 stromal induction in, **42**
 - CD14 in, **45**
 - CD15 in, **52**
 - CD30 in, **80**
 - CD45RA in, **99**
 - CD57 in, **107–108**
 - CD79a in, **119**
 - CD123 in, **133**
 - desmin in, **217**
 - Fli-1 in, **191**
 - MUM1 in, **222**
 - Pax-5 in, **182**
 - staging with CD8, **34**
 - terminal deoxynucleotidyltransferase (TdT) in, **167**
- CLL (chronic lymphocytic leukemia)
- CD23 in, **72–74**
 - CD34 in, **94**
- clotted blood
- CD34 in, **90, 91**
 - proper fixation for hemoglobin A staining, **159**
- cluster of differentiation, of markers, 13–141
- CML: See chronic myeloid leukemia.
- CMML: See chronic myelomonocytic leukemia.
- colon carcinoma, metastatic tumor diagnostic considerations, **249**
- common leukocyte antigen, 97–103
- CR1, 95–97
- crush artifacts, tissue processing considerations, 3
- crushed bone marrow specimen, CD20 in, **63**
- Cyclin D1, 194–199
- in adipocytes, **195**
 - in atypical lymphoid aggregates, **196**
 - biopsy sample with AZF fixative, **9**
 - in chronic lymphocytic leukemia, **197**
 - in dendritic cells, **196**
 - as Dutcher body marker, **199**
 - in follicular lymphoma, **196**
 - in hairy cell leukemia, **197**
 - in IgA myeloma, **199**
 - localization in diagnosis, 2
 - in lymphoid aggregates, **196**
 - in mantle cell lymphoma, **197–198**
 - in normal bone marrow, **194–195**
 - in osteoblasts, **195**
 - in peripheral T-cell lymphoma, **196**
 - in pleomorphic mantle cell lymphoma, **198**
 - recommended panel applications, 253
- cymase, in mast cells, **164**
- cytokeratin
- acute leukemia diagnostic considerations with acute myeloid leukemia, **243**
 - localization in diagnosis, 2
- cytologic details, tissue processing implications for, 3
- cytoplasmic antigens, flow cytometry diagnostic role, 3
- cytoplasmic antigens, in reactive T cells, **18**
- cytoplasmic expression
- of CD5, **28**
 - of CD22, **69**
 - of CD30 in normal bone marrow, **79**
 - of CD61, **110**
- cytoplasmic granules, biopsy sample with AZF fixative, **8**
- cytoplasmic localization, of immunohistochemical markers, 2
- cytoplasmic ruffles
- with CD14, **45**
 - with CD20, **59**
- cytoplasmic staining, biopsy sample with AZF fixative, **8**
- cytotoxic molecules, 211–213
- ## D
- D11S287E, 194–199
- DBA.44, biopsy sample with AZF fixative, **9**
- DeCal Retrieval Solution, for, decalcification, 6
- decalcification, diagnostic significance, 3, 5
- dendritic cell neoplasms, recommended panels, 253
- dendritic cells
- actin association with, **217**
 - CD14 in, **48**
 - CD15 in, **52**
 - CD16 in, **56**
 - Cyclin D1 in, **196**
 - follicular, CD23 in, **70**
 - identified in precursor B-cell lymphoblastic leukemia with CD68 marker (PG-M1) and lysozyme, **117**
 - vascular cell adhesion molecule in, **220**
- dendritic extensions of stromal cells, CD10 in, **38, 39**
- dendritic histiocytes, biopsy sample with AZF fixative, **8**
- dendritic pattern, of CD14 in normal bone marrow, **47**
- dendritic stromal cells
- CD10 positivity in some neoplasms, **42**
 - CD10 vs reticulin staining, **43**
- desmin
- in bone marrow, classical Hodgkin lymphoma present, **217**
 - in classical Hodgkin lymphoma, **217**
 - localization in diagnosis, 2
- differentiation, cluster of, 13
- diffuse large B-cell lymphoma
- Bcl-6 in, **202–203**
 - CD5 in, **30**
 - CD20 in, **63**
 - CD138 in, **139**
 - immunoglobulins in, **206**
 - MUM1 in, **223**
- DNA deoxynucleotidyltransferase, 167–173
- DNA nucleotidyltransferase, 167–173
- DRAP-27, 36–38
- Dutcher bodies, Cyclin D1 as marker for, **199**
- dysplastic megakaryocytes
- concentration of von Willebrand factor in, **176**
 - expressing CD61, **112**

E

- E2, 123–127
- EBER1 probe, Epstein-Barr virus demonstration in AZF-fixed biopsy, **10**
- EBV, recommended panel applications, 253
- EC 3.1.3.4, 97–103
- ELFT, 51–53
- EMA (epithelial membrane antigen)
 - acute leukemia diagnostic considerations with acute erythroid leukemia, **243**
 - localization in diagnosis, 2
- embedding, diagnostic implications, 5
- endocam, 81–84
- endosteal lining cells
 - actin expression in, **218**
 - CD8 in, **34**
 - CD10 in, **44**
 - CD56 and CD57 contrasted, **108**
 - Fli-1 in, **192**
 - Ki-67 negativity in adult bone marrow, **209**
- endosteal localization, CD56 in, **106**
- endothelial cells
 - Bcl-6 in, **201**
 - CD8 in, **33**
 - CD9 in, **37**
 - CD14 in, **46**
 - CD34 in with mantle cell lymphoma, **94**
 - CD61 in, **110**
 - CD99 in, **125**
 - Fli-1 in, **192**
 - megakaryocyte association with, **177**
 - von Willebrand factor in, **175**
- EnVision, CD10 sensitivity, **39**
- eosinophils, in biopsy sample with AZF fixative, **10**
- epithelial membrane antigen
 - acute leukemia diagnostic considerations with acute erythroid leukemia, **243**
 - localization in diagnosis, 2
- epithelioid histiocytes, CD4 in, **26**
- epitope antigenicity, tissue processing implications for, 3
- Epstein-Barr virus, in biopsy sample with AZF fixative, **10**
- E-rosette receptor, 16–17
- erythroid acute leukemia, CD79a in, **123**
- erythroid hyperplasia
 - CD15 in, **51**
 - hemoglobin A in, **160**
- erythroid hypoplasia, biopsy sample with AZF fixative, 7
- erythroid leukemia, PU.1 in, **190**
- erythroid maturation, differential expression of hemoglobin A, **159**
- erythroid precursors, biopsy sample with AZF fixative, 7
- erythroid precursors
 - CD35 in, **97**
 - CD99 negativity in, **127**
 - CD235a in, **140**
 - glycophorin A expression, **140**
- erythroleukemia, acute leukemia diagnostic considerations with CD235a, **241**
- essential thrombocythemia, Fli-1 in, **193**

F

- F8-related antigen: See von Willebrand factor.
- FceRII, 69–74
- FCT3A, 51–53
- fibrotic bone marrow specimen, CD20 in, **63**
- fixation
 - biopsy preparation for diagnosis, 1
 - diagnostic significance, 3–4
 - recent progress, 10
- FL: See follicular lymphoma.
- Fli-1, 191–193
 - in acute erythroid leukemia, **193**
 - in acute myeloid leukemia, **193**
 - in classical Hodgkin lymphoma, **191**
 - in endosteal lining cells, **192**
 - in endothelial cells, **192**
 - in essential thrombocythemia, **193**
 - localization in diagnosis, 2
 - metastatic tumor diagnostic considerations, **252**
 - in normal bone marrow, **191–192**
 - overexpression in abnormal megakaryocytes, **193**
- flow cytometry, diagnostic role, 1, 3
- focal bone marrow involvement in CLL, CD23 in, **73**
- focally hypocellular bone marrow, CD79a in, **120**
- follicular colonization of benign interstitial aggregates, CD35 in, **96**
- follicular dendritic cells
 - CD21 and CD23 vs CD35 demonstration, **96**
 - CD23 in, **70**
 - CD35 in with lymphoplasmacytic lymphoma, **97**
- follicular lymphoma
 - Bcl-2 positivity in, **44**
 - Bcl-6 in, **202**
 - Bcl-6 positivity in, **44**
 - CD3 in, **18**
 - CD5 in, **30**
 - CD10 in, 43, **44**
 - CD20 in, 60, **61**
 - CD21 in, 66, **67**
 - CD23 in, **71**
 - CD35 in, **96**
 - CD79a in, 120, **121**
 - CD138 vs CD79a in, **120**
 - Cyclin D1 in, **196**
 - mast cell tryptase in, **161**
 - MUM1 in, **223**
 - Pax-5 highlighting of intrasinusoidal B-cell distribution, **184**
 - Pax-5 in, **179**
 - Pax-5 vs CD20 in, **183**
- formaldehyde, tissue processing considerations, 4
- formalin
 - in biopsy fixation, 4
 - implications for decalcification in tissue processing, 6
- FUC-TIV, 51–53
- FUT4, 51–53

G

- glycocalicin, 109, 113
- glycophorin A, 140–141
 - in acute erythroid leukemia, **141**
 - in acute myeloid leukemia, **141**
 - in erythroid precursors, **140**
 - vs hemoglobin A staining, **158**
 - in myelodysplastic syndrome, **140, 141**
 - recommended panel applications, 253
- glycophorin B, 140–141
- glycophorin-C
 - biopsy sample with AZF fixative, 7
 - recommended panel applications, 253
- glycophorins, localization in diagnosis, 2
- glycoprotein IIIa, 109–113
- Golgi area, vascular cell adhesion molecule in, **220**
- Golgi-type
 - CD8 expression, **35**
 - CD30 expression, **80**
 - concentration of von Willebrand factor in dysplastic megakaryocytes, **176**
- Golgi-type localization, of immunohistochemical markers, 2
- Gooding and Stewart decalcification fluid, decalcification time and processing implications, 5, 6s
- GP3A (platelet glycoprotein IIIA), 109–113
- gp67, 84–87
- gp105-120, 88–95
- gp110, 114–118
- GPIb[alpha], 109, 113
- GPIba, 109, 113
- GpIIa, 81–84
- granzyme B
 - localization in diagnosis, 2
 - in normal bone marrow, **212**
 - in peripheral T-cell lymphoma, **212**
 - recommended panel applications, 253
 - in T-cell large granular lymphocytic leukemia, **213**
- GYPA (glycophorin A), 140–141
- GYPB (glycophorin B), 140–141

H

- hairy cell leukemia
 - biopsy sample with AZF fixative, **9**
 - CD5 in, **30**
 - CD20 vs CD79a in, **122**
 - CD23 in, **72**
 - CD79a in, **122**
 - CD123 in, **134**
 - Cyclin D1 in, **197**
 - κ - λ immunoglobulin comparison to detect, **204**
 - Ki-67 in, **210**
 - Pax-5 in, **184**
 - TRAP in, **225**
- Hammersmith protocol, turnaround time implications, 6
- HCDM, vs HLDA nomenclature, 13
- HCL: See hairy cell leukemia.
- hematodermic neoplasm
 - CD56 in, **106**
 - PU.1 in, **188**
- hematogones
 - CD10 in, **41**
 - CD22 in, **68**
 - CD79a in, **120**
 - CD79a in, **121**
 - CD79a vs TdT in demonstrating maturational rows, **168**
 - maturational rows demonstrated with TdT, **168**
- hematopoietic precursor cells, CD99 in, **125**
- hemoglobin
 - acute leukemia diagnostic considerations with acute myeloid leukemia, **241**
 - localization in diagnosis, 2
 - recommended panel applications, 253
- hemoglobin A staining, 157–160
 - in acute erythroid leukemia, **160**
 - in acute myeloid leukemia, **160**
 - in aplastic anemia, **160**
 - in bone marrow, hypoplastic, **160**
 - to determine myeloid-erythroid ratio, **154**
 - in erythroid hyperplasia, **160**
 - in erythroid maturation, **159**
 - vs glycophorin A, **158**
 - in hypercellular bone marrow, **158**
 - in hypoplastic bone marrow, **160**
 - in myelodysplastic syndrome, **160**
 - in myeloid hyperplasia, **158**
 - in neutrophil hyperplasia, **158**
 - proper fixation for, in clotted blood sections, **159**
 - in thin tissue sections, **159**
- hemophagocytic histiocytes, CD4 in, **26**
- hemophagocytic syndrome
 - CD5 in, **30**
 - CD14 in, **48, 49**
 - CD68 (via PG-M1) in, 117, **118**
 - vimentin in, **216**
- hemorrhage artifacts, tissue processing considerations, 3
- histiocytic cells, CD15 in, **52**
- histiocytic neoplasms, recommended panels, 253
- histologically unremarkable bone marrow, CD2 in, **16**
- HIV+ patient with atypical lymphoid aggregate, CD3 in, **22**
- HLA-DR
 - acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 - biopsy sample with AZF fixative, 7
 - localization in diagnosis, 2
- HLDA, vs HCDM nomenclature, 13
- HNK-1 (human natural killer-1), 107–109
- Hodgkin cells, Pax-5 to distinguish from megakaryocytes, **182**
- Hodgkin lymphoma, recommended panels, 253
- human natural killer-1, 107–109
- hydrochloric-formic acid, decalcification time and processing implications, 5
- hyperblastic bone marrow, CD34 in, **90**
- hypercellular bone marrow, hemoglobin A staining in, **158**

hypocellular bone marrow
 in biopsy sample with AZF fixative, **9**
 CD34 in, **91**
 CD57 in, **108**
 CD79a in, **120**
 CD117 in, **132**
 κ - λ immunoglobulin comparison to detect, **204**
 MUM1 in, **221**
 with increased hematogones, CD3 in, **22**, CD34 in, **22**

hypoplastic bone marrow, hemoglobin A in, **160**

I

Ig- α , 119–123

IgA, recommended panel applications, 253

IgA multiple myeloma, CD45RA in, **100**

IgA myeloma
 CD138 in, **135**
 Cyclin D1 in, **199**

IgD, recommended panel applications, 253

IgE, recommended panel applications, 253

IgG, recommended panel applications, 253

IgG- κ multiple myeloma, MUM1 in, **222**

IgM, recommended panel applications, 253

IgM+ myeloma, CD45RA in, **100**

IL3RA, 133–134

immunoglobulins, 203–208
 in acute myeloid leukemia, **208**
 in chronic myelomonocytic leukemia, **208**
 in diffuse large B-cell lymphoma, **206**
 in hairy cell leukemia, **204**
 in hypocellular bone marrow, **204**
 immunoglobulins, localization in diagnosis, 2
 in lymphoplasmacytic lymphoma, **206**, **207**
 in mantle cell lymphoma, 207, **208**
 in marginal zone lymphoma, **207**
 in monotypic plasma cells, **204**
 in multiple myeloma, **205**
 in non-Hodgkin lymphoma, **204**
 in plasmacytosis, **205**
 in reactive plasmacytosis, **205**

immunohistochemistry, diagnostic role, 1, 3

in situ hybridization, in biopsy sample with AZF fixative, **10**

indented nuclei, residual disease demonstration, **9**

indolent systemic mastocytosis, CD117 in, **132**

integrin [beta]4, 109–113

interferon regulatory factor 4, 221–223

interpretation, diagnostic implications, 1

interstitial B-lymphoid cell infiltrate example, **9**

interstitial aggregates, CD35 and follicular lymphoma colonization of, **96**

interstitial chronic lymphocytic leukemia, CD23 in, **73**, **74**

interstitial lymphoid aggregates, CD3 in, **22**, CD20 in, **22**

interstitial T cells, CD8 in, **33**

interstitium, CD14 in, **45**, CD23 in, **70**

intestinal myeloid sarcoma
 CD33 in, **87**
 myeloperoxidase expression in, **87**

intrasinusoidal localization
 of CD79a, **121**
 Pax-5 highlighting in B-cell lymphoma, **184**

IRF4, 221–223

ISM (indolent systemic mastocytosis), CD117 in, **132**

ITGB3, 109–113

K

κ , recommended panel applications, 253

κ Ig light chain mRNA, biopsy sample with AZF fixative, **9**

Ki-1 antigen, 78–81

Ki-67, 209–210
 acute leukemia diagnostic considerations with acute myeloid leukemia, **245**
 biopsy sample with AZF fixative, **10**
 in hairy cell leukemia, **210**
 localization in diagnosis, 2
 in multiple myeloma, **210**
 in normal bone marrow, **209**
 in precursor B-cell lymphoblastic leukemia, **210**
 recommended panel applications, 253

KP-1
 acute leukemia diagnostic considerations with acute myelomonocytic leukemia, **239**
 to demonstrate CD68 in chronic myeloid leukemia, **116**
 to demonstrate CD68 in chronic myelomonocytic leukemia, **116**
 to demonstrate CD68 in normal bone marrow, **115**

L

λ , recommended panel applications, 253

λ mRNA, biopsy sample with AZF fixative, **9**

L3T4, 24–26

laboratory, procedure variability, 1

laboratory, processing volume turnaround time implications, 6

lactoferrin, 153

laminin in normal bone marrow, **221**

Langerhans cell histiocytosis, CD1a in, **14**, **15**

LAZ3 (lymphoma-associated zinc finger gene on chromosome 3), 201–203

LCH (Langerhans cell histiocytosis), CD1a in, **14**, **15**

Leu-1, 27–30

Leu-7, CD57 in, **107**

Leu-16, 57–63

Leu-19, 104–107

Leu-20, 69–74

Lewis x, 51–53

LFA-2, 16–17

light chain demonstration, in biopsy sample with AZF fixative, **9**

lobular breast carcinoma, metastatic tumor diagnostic considerations, **252**

localization, of immunohistochemical markers, 2

low-affinity IgE receptor, 69–74

Lowy formalin mercuric chloride
 decalcification applications, 5
 fixation time and implications, 4

- LPL: See lymphoplasmacytic lymphoma.
- lung carcinoma, metastatic tumor diagnostic considerations, **249**
- lupus erythematosus, systemic, CD20 in, **59**
- Ly-1, 27–30
- Ly5, 97–103
- lymphoblastic leukemia, acute, CD34 14 in days after chemotherapy, **93**
- lymphocyte-function antigen-2, 16–17
- lymphocytes, activated, CD25 in, **77**
- lymphocytes, maturing, CD10 in, **39**
- lymphocytosis, CD8 in, **35**
- lymphoid aggregates
 - atypical, CD3 in, **22**
 - benign, CD4 in, **25**
 - CD34 in with mantle cell lymphoma, **94**
 - Cyclin D1 in, **196**
 - large, CD20 in, **60, 63**
 - mast cell tryptase around, **164**
 - reactive, CD23 in, **70**
 - S-100 protein in, **219**
 - terminal deoxynucleotidyltransferase (TdT) induction around, **169**
 - very small, CD20 in, **61**
- lymphoid cells
 - CD56 in, **105**
 - immature, CD10 in, **38**
 - small, CD9 in, **37**
- lymphoid clusters, CD23 in, **74**
- lymphoma-associated zinc finger gene on chromosome 3, 201–203
- lymphoplasmacytic lymphoma
 - CD20 in, **62**
 - CD20 vs CD79a in, **122**
 - CD35 in follicular dendritic cells with, **97**
 - CD45RA in, **101**
 - CD79a in, **122**
 - CD138 in, **139**
 - immunoglobulins in, **206, 207**
 - infiltrated by benign T cells, CD3 in, **23**
 - MUM1 in, **222**
- lysozyme, 153, 199–200
 - in acute erythroid leukemia, **200**
 - acute leukemia diagnostic considerations with acute myelomonocytic leukemia, **239**
 - in acute myeloid leukemia, **200**
 - in chronic myelomonocytic leukemia, **200**
 - to identify precursor B-cell lymphoblastic leukemia, **117**
 - localization in diagnosis, **2**
 - recommended panel applications, **253**
- M**
- mAbs (monoclonal antibodies), CD nomenclature of, **13**
- macronucleoli, to identify tumor cells, **138**
- macrophages
 - CD14 in, **45, 46, 48**
 - CD16 in, **56, 57**
 - CD68 vs CD16 in, **57**
- mantle cell lymphoma
 - CD5 in, **29**
 - CD20 in, **60, 61**
 - CD23 in, **72**
 - CD34 in, **94**
 - Cyclin D1 in, **197–198**
 - immunoglobulins in, **207, 208**
 - infiltrated by benign T cells, CD3 in, **24**
 - Pax-5 in, **184–185**
- marginal zone lymphoma
 - Bcl-6 in, **201**
 - CD138 in, **139**
 - CD20 in, **62**
 - CD21 in, **66, 67**
 - CD23 in, **71**
 - CD30 in, **81**
 - CD68 (via PG-M1) in, **115**
 - immunoglobulins in, **207**
 - Pax-5 in, **178, 185**
- markers, cluster of differentiation, 13–141
- mast cell disease
 - CD33 in, **87**
 - myeloperoxidase expression in, **87**
- mast cell tryptase, 161–166
 - in chronic myeloid leukemia, **165–166**
 - in chronic myelomonocytic leukemia, **166**
 - in follicular lymphoma, **161**
 - localization in diagnosis, **2**
 - around lymphoid aggregates, **164**
 - in normal bone marrow, **161**
 - in postmortem specimens, **162**
 - in reactive bone marrow, **162**
 - in rheumatoid arthritis, **162**
 - in systemic mastocytosis, **162–164**
- mast cells
 - benign, CD33 in, **86**
 - CD9 in, **37**
 - CD117 positivity in acute erythroid leukemia, **131**
 - chymase in, **164**
- mastocytosis
 - CD25 in, **76, 77**
 - recommended panels, **253**
- mature B-cell lymphoma, Pax-5 vs CD20 in, **183**
- mature granulocytes, CD99 negativity in, **127**
- maturing lymphocytes, CD10 in, **39**
- MB1, 119–123
- MCL: See mantle cell lymphoma.
- MCT, recommended panel applications, **253**
- megakaryoblastic leukemia, acute
 - acute leukemia diagnostic considerations with vimentin **243**
 - CD31 in, **83**
- megakaryoblasts, CD61 in, **111**
- megakaryocytes
 - acute leukemia diagnostic considerations with vimentin **243**
 - association with endothelial cells of marrow sinusoids, **177**
 - CD9 in, **36**
 - CD34 in, **89, 90, 95**
 - CD61 in, **110, 111, 112**
 - CD99 in, **126**
 - concentration of von Willebrand factor in dysplastic, **176**
 - dendritic pattern of CD14 positivity, **47**
 - Fli-1 overexpression in abnormal, **193**
 - Pax-5 to distinguish from Hodgkin cells, **182**
 - staining for von Willebrand factor, **174, 175**

- megaloblastoid dyserythropoiesis, biopsy sample with AZF fixative, **7**
- membranous expression
of CD5, **28**
of CD8, **35**
of CD9, **36**
of CD22, **69**
of CD45RO in peripheral T-cell lymphoma, **103**
membranous expression, of CD61, **110, 111**
- membranous localization, of immunohistochemical markers, **2**
- mercurial fixatives, in biopsy fixation, **4**
- Merkel cell carcinoma, acute leukemia diagnostic considerations with pancytokeratin **243**
- metamyelocytes, CD16 in, **55**
- metastatic tumors, diagnostic considerations, 247–252
- MGC3969, 57–63
- MGUS (monoclonal gammopathy of unknown significance), CD56 in, **105**
- MIC2, 123–127
- MIC2X, 123–127
- MIC2Y, 123–127
- monoblastic leukemia, acute
CD33 in, **87**
myeloperoxidase expression in, **87**
- monoclonal antibodies (mAbs), CD nomenclature of, **13**
- monoclonal gammopathy, CD56 in, **105**
- monoclonality, chain restriction as support for, **138**
- monocytes
biopsy sample with AZF fixative, **8**
CD14 in, **45**
dendritic pattern of CD14 positivity, **47**
circulating, CD14 in, **46**
- monocytic cells, Bcl-6 in, **201**
- monocytoid nuclei, residual disease demonstration, **9**
- mononuclear bone marrow cell, CD21 in, **65**
- monotypic plasma cells, κ - λ immunoglobulin comparison to detect, **204**
- MPO: See myeloperoxidase.
- MRP-1, 36–38
- MS4A1, 57–63
- mucin metastatic tumor diagnostic considerations, **248**
- multiple myeloma
CD10 stromal induction in, **42**
CD3 in, **18**
CD99 in, **126**
CD138 in, **136, 137**
immunoglobulin G in, **205**
Ki-67 in, **210**
metastatic tumor diagnostic considerations, **249**
MUM1 in, **222**
- multiple myeloma oncogene 1, 221–223
- MUM1, 221–223
biopsy sample with AZF fixative, **8, 10**
in classical Hodgkin lymphoma, **222**
in diffuse large B-cell lymphoma, **223**
in follicular lymphoma, **223**
in hypocellular bone marrow, **221**
in IgG- κ multiple myeloma, **222**
localization in diagnosis, **2**
in lymphoplasmacytic lymphoma, **222**
in multiple myeloma, 137, **222**
in reactive plasmacytosis, **221**
recommended panel applications, 253
- myelodysplastic syndrome
biopsy sample with AZF fixative, **7**
CD31 vs von Willebrand factor in, **82**
CD61 in, **110**
CD61 in, **111**
CD235a in, **140, 141**
glycophorin A expression, 140, **141**
hemoglobin A in, **160**
recommended panels, 253
von Willebrand factor in, **177**
- myelogenous leukemia, after induction chemotherapy, CD3 in, **18**
- myeloid cells, CD45RO in, **103**
- myeloid hyperplasia, hemoglobin A staining in, **158**
- myeloid hypoplasia, vimentin in, **215**
- myeloid leukemia, PU.1 in, **190**
- myeloid leukemia, acute. See acute myeloid leukemia.
- myeloid leukemia, undifferentiated acute. See undifferentiated acute myeloid leukemia.
- myeloid leukemias, CD99 in, **125**
- myeloid precursors
Bcl-2 in, **227**
CD138 and MUM-1 negativity, **137**
myeloperoxidase in, **154**
- myeloid sarcoma, intestinal
CD33 in, **87**
myeloperoxidase expression in, **87**
- myeloid-erythroid ratio, determined with myeloperoxidase and hemoglobin A staining, **154**
- myeloma, multiple, CD99 in, **126**
- myelomonoblastic leukemia, acute, CD31 in, 82, **83**
- myelomonocytic cells, biopsy sample with AZF fixative, **8**
- myelomonocytic leukemia, CD45RA in, **100**
- myeloperoxidase, 153–157
in acute hypocellular leukemia, **155**
acute leukemia diagnostic considerations with acute bilineal leukemia, **246**
acute leukemia diagnostic considerations in acute myelomonocytic, monocytic, and undifferentiated leukemias, **238**
in acute lymphoblastic leukemia, **157**
in acute monoblastic leukemia, **87**
in acute myeloid leukemia, **155, 156**
biopsy sample with AZF fixative, **7**
vs CD15 in acute myeloid leukemia, **53**
vs CD117 in acute myeloid leukemia, **130**
in chronic myeloid leukemia, 153, **154**
in chronic myelomonocytic leukemia, **154**
to determine myeloid-erythroid ratio, **154**
false negatives with, **155**
in intestinal myeloid sarcoma, **87**
localization in diagnosis, **2**
vs lysozyme in CMML, AML, and acute erythroid leukemia, **200**
in mast cell disease, **87**
in myeloid precursors, **154**
in neutropenia, **154**
in neutrophil precursors, **154**
in normal bone marrow, **153**
in paratrabeular localization, **154**
in precursor B-cell lymphoblastic leukemia, **157**
recommended panel applications, 253

myeloproliferative disease

CD20 in, **63**

CD30 in, **79**

CD117 in, **133**

recommended panels, 253

MZL. See marginal zone lymphoma.

natural killer cells, CD56 in, **105**

N

NCAM (neural cell adhesion molecule), 104–107

necrotic tissue, metastatic tumor diagnostic considerations, **248**

neoplastic lymphoid aggregates, CD10 in, **41**

neoplastic plasma cells, CD56 in, **106**

neural cell adhesion molecule, 104–107

neuroblastoma

metastatic tumor diagnostic considerations, 249, 250, 251, **252**

neurofilaments

localization in diagnosis, 2

metastatic tumor diagnostic considerations, **251**

neuron-specific enolase

localization in diagnosis, 2

metastatic tumor diagnostic considerations, 250, **251**

neutropenia, myeloperoxidase in, **154**

neutrophil hyperplasia, hemoglobin A staining in, **158**

neutrophil precursors, myeloperoxidase in, **154**

neutrophils

CD10 in, 38, 39, **40**

CD16 in, **55**

nitric acid, decalcification time and processing implications, 5

NK (natural killer) cells, CD56 in, **105**

NKH1, 104–107

NLPHL (nodular lymphocyte predominance Hodgkin lymphoma), CD20 in, **58**

nodal classical Hodgkin lymphoma, CD20 in, **58**

nodal diffuse large B-cell lymphoma

CD3 in, **22**

CD20 in, **22**

nodal peripheral T-cell lymphoma, CD5 in, **29**

nodular lymphocyte predominance Hodgkin lymphoma, CD20 in, **58**

nodular sclerosis Hodgkin lymphoma, CD99 in, **126**

non-Hodgkin lymphoma

κ - λ immunoglobulin comparison in diagnosis, **204**

staging with actin, **218**

nonmalignant atypical T cells, CD3 in, **20**

non-neoplastic hematopoiesis, Pax-5 in, **179**

normal bone marrow

Bcl-2 in, 226, **227**

Bcl-6 in, **201**

CD3 in, **17**

CD4 in T lymphocytes in, **24–25**

CD5 in, **27**

CD8 in, **33**

CD14 in, 45, **46**

CD15 in, **51**

CD16 in, **54–55**

CD20 in, 58, **59**

CD21 in, 64, **65**

CD23 in, **70**

CD25 in, **75**

CD30 in, **78–79**

CD31 in, **81–82**

CD33 in, **85–86**

CD34 in, **88**

CD35 in, **95**

CD42b in, **113**

CD45RA in, **98–99**

CD56 in, **104**

CD57 in, **107–108**

CD61 in, **110**

CD68 in, 114, **115**

CD99 in, **124**

CD117 in, **128**

CD123 in, **133–134**

CD138 in, **135**

Cyclin D1 in, **194–195**

dendritic pattern of CD14 positivity, **47**

Fli-1 in, **191–192**

granzyme B in, **212**

Ki-67 in adult, **209**

laminin in, **221**

mast cell tryptase in, **161**

myeloperoxidase in, **153**

Pax-5 in, **178**

PU.1 in, **186**

S-100 protein in, **219**

terminal deoxynucleotidyltransferase (TdT) in, **167–169**

TRAP in, **224**

vascular cell adhesion molecule in, **220**

vimentin in, **214**

von Willebrand factor in, **174**

normochromic normocytic anemia, CD23 in, **71**

NPM1, localization in diagnosis, 2

NPM1, recommended panel applications, 253

NSE (neuron-specific enolase)

localization in diagnosis, 2

metastatic tumor diagnostic considerations, 250, **251**

nuclear antigens, flow cytometry diagnostic role, 3

nuclear localization, of, immunohistochemical markers, 2

nuclear staining pattern, in biopsy sample with AZF fixative, **9**

nucleic acid, tissue processing considerations, 4

nucleophosmin biopsy sample with AZF fixative, **8**

nucleosidetriphosphate, 167–173

O

OCT2

biopsy sample with AZF fixative, **10**

localization in diagnosis, 2

recommended panel applications, 253

osteoblasts

CD99 in, **125**

Cyclin D1 in, **195**

metastatic tumor diagnostic considerations, **251**

osteocytes, metastatic tumor diagnostic considerations, **251**

osteosarcoma, CD99 in, **125**

P

- p24, 36–38
- p53, biopsy sample with AZF fixative, **8**
- p53, localization in diagnosis, 2
- p67, 84–87
- pancytokeratin
 - acute leukemia diagnostic considerations with acute myeloid leukemia, **243**
 - metastatic tumor diagnostic considerations, **248**
- pancytopenia
 - CD99 in, **125**
 - CD117 in, **131**
- panels, recommended, 253
- paraffin embedding
 - biopsy preparation for diagnosis, 1
 - diagnostic implications, 5
 - turnaround time and diagnostic implications, 6
- paratrabeular lining cells, actin presence in classical Hodgkin lymphoma sample, **218**
- paratrabeular localization
 - CD56 in, 106, **107**
 - of CD79a, **120**
 - of CD117 after chemotherapy, **132**
 - CD138 in, **138**
 - myeloperoxidase in, **154**
- parvovirus B19
 - biopsy sample with AZF fixative, 7
 - localization in diagnosis, 2
 - recommended panel applications, 253
- Pax-5, 178–185
 - in acute erythroid leukemia, **181**
 - acute leukemia diagnostic considerations with acute megakaryoblastic leukemia, **244**
 - in acute myeloid leukemia, **182**
 - biopsy sample with AZF fixative, **10**
 - vs CD20 in follicular lymphoma, **183**
 - in chronic myelomonocytic leukemia, **179**
 - in classical Hodgkin lymphoma, **182**
 - in follicular lymphoma, 183, **184**
 - in hairy cell leukemia, **184**
 - intrasinusoidal localization, **184**
 - in linear arrangement of, 179, **180**
 - localization in diagnosis, 2
 - in mantle cell lymphoma, **184–185**
 - in marginal zone lymphoma, 178, **185**
 - in mature B-cell lymphoma, **183, 184**
 - in non-neoplastic hematopoiesis, **179**
 - in normal bone marrow, **178**
 - in precursor B-cell lymphoblastic leukemia, **180–181**
 - recommended panel applications, 253
 - reliability after rituximab therapy, **180**
 - vs terminal deoxynucleotidyltransferase (TdT) in non-neoplastic hematopoiesis, **179**
- PECAM-1, 81–84
- perforin
 - localization in diagnosis, 2
 - recommended panel applications, 253
- pericytes, CD9 in, **36, 37**
- peripheral blood lymphocytosis, biopsy sample with AZF fixative, **9**
- peripheral T-cell lymphoma
 - Bcl-6 in, **202**
 - CD2 in, **16–17**
 - CD3 in, **21**
 - CD5 in, **29**
 - CD7 in, **32**
 - CD8 in, **35**
 - CD14 in, 48, **49**
 - CD45RO in, **102–103**
 - CD57 in, **108–109**
 - CD68 (via PG-M1) in, **117**
 - Cyclin D1 in, **196**
 - granzyme B in, **212**
 - TIA-1 (T-cell intracellular antigen-1) in, **212**
- perivascular distribution, CD138 in, **135**
- perivascular monocytic cells
 - Bcl-6 in, **202**
 - CD14 in, **47**
- perivascular plasma cells, CD9 in, **36**
- perivascular T cells, CD3 in, **20**
- PG-M1
 - acute leukemia diagnostic considerations with acute myelomonocytic leukemia, **239**
 - to demonstrate CD68 in chronic myeloid leukemia, **116**
 - to demonstrate CD68 in chronic myelomonocytic leukemia, **116**
 - to demonstrate CD68 in hemophagocytic syndrome, 117, **118**
 - to demonstrate CD68 in marginal zone lymphoma, **115**
 - to demonstrate CD68 in peripheral T-cell lymphoma, **117**
 - to demonstrate CD68 in precursor B-cell lymphoblastic leukemia, **116–117**
 - recommended panel applications, 253
- phagocytic histiocytes, biopsy sample with AZF fixative, **8**
- phosphate buffer, in biopsy fixation, 4
- plasma cell disorders, recommended panels, 253
- plasma cell myeloma, CD79a in, **121**
- plasma cells
 - CD9 in, **37**
 - CD10 in, **41**
 - CD45RO in, **103**
 - CD56 in benign, **105**
 - CD79a in, **120**
 - CD99 in, **126**
 - CD138 in, **135**
 - plasma cells, CD138 marking after transplantation, **138**
- plasmacytoid dendritic cells, CD56 in, **106**
- plasmacytosis, immunoglobulin A vs G in, **205**
- platelet glycoprotein IIIA, 109–113
- platelets
 - CD9 in, **36**
 - CD42b in, **113**
 - CD61 in, **110**
- pleomorphic mantle cell lymphoma, Cyclin D1 in, **198**
- polycythemia vera, CD117 in, **133**
- postmortem specimens, mast cell tryptase in, **162**
- PRAD1, 194–199

- precursor B-cell acute lymphoblastic leukemia
 Bcl-2 in, **228**
 CD10 contrasted with CD68 (via PG-M1) in, **117**
 CD10 in, **40**
 CD20 in, **63**
 CD31 in, **84**
 CD34 in, 91, 14 days after induction chemotherapy, **92**
 CD45RA in, **101**
 CD68 (via PG-M1) in, **116–117**
 CD79a in, **122, 123**
 CD99 in, **127**
 CD117 in, **129**
 Ki-67 in, **210**
 myeloperoxidase in, **157**
 Pax-5 in, **180–181**
 PU.1 in, **189**
 terminal deoxynucleotidyltransferase (TdT) in, **169–171**
 von Willebrand factor in, **176**
- precursor T-cell acute lymphoblastic leukemia, CD1a in, **14**
- precursor T-lymphoblastic leukemia, CD3 in, **23**
- preparation of tissue for diagnosis, 3
- processing of tissue for diagnosis, 3
- proerythroblasts, giant, biopsy sample with AZF fixative, 7
- promonocytes
 biopsy sample with AZF fixative, **8**
 Bcl-2 in, **227**
- promyelocytic leukemia, acute
 CD3 in, **21**
 CD14 in, **48**
 von Willebrand factor in, **176**
- PTCL. See peripheral T-cell lymphoma.
- PU.1, 185–190
 in acute myeloid leukemia, **187**
 in chronic myeloid leukemia, **190**
 in chronic myelomonocytic leukemia, **189**
 in erythroid leukemia, **190**
 in hematodermic neoplasm, **188**
 localization in diagnosis, 2
 in myeloid leukemia, **190**
 in normal bone marrow, **186**
 in precursor B-cell lymphoblastic leukemia, **189**
 in pure erythroid acute leukemia, **190**
 recommended panel applications, 253
 in undifferentiated acute leukemia, **187**
- pure erythroid acute leukemia
 CD79a in, **123**
 PU.1 in, **190**
- R**
- RDO, decalcification time and processing implications, 5
- reactive bone marrow
 CD20 in, **59**
 CD20 in, **59**
 CD22 in mild, **68**
 CD79a in, **119**
 CD117 in, **129**
 mast cell tryptase in, **162**
- reactive lymphoid aggregate, CD21 in, **65**
- reactive plasma cells, CD138 in, **135**
- reactive plasmacytosis
 immunoglobulin A vs G in, **205**
 MUM1 in, **221**
- reactive T cells
 CD3 in, **18, 19**
 CD7 in, **31**
- recommended panels, 253
- Reed-Sternberg cells, in biopsy sample with AZF fixative, **10**
- refractory anemia with excess blasts
 CD7 in, **31**
 CD8 in, **35**
 CD34 in, **88**
 CD61 in, **111**
 TIA-1 (T-cell intracellular antigen-1) in, **211**
- refractory anemia with myeloid hyperplasia, vimentin in, **216**
- residual disease, in biopsy sample with AZF fixative, **9**
- resin embedding
 diagnostic implications, 5
 turnaround time and diagnostic implications, 6
- reticulin staining, vs CD10 marker in dendritic stromal cells, **43**
- retrieval, of antigens, methods and recommendations, 5–6
- rheumatoid arthritis, mast cell tryptase positivity in, **162**
- rituximab therapy, CD20, CD79a, and Pax-5 followup, **180**
- rosebud, 272
- ruffles, cytoplasmic
 with CD14, **45**
 with CD20, **59**
- S**
- S-100 protein
 localization in diagnosis, 2
 in normal bone marrow, adipocytes, and small stromal cells, **219**
 recommended panel applications, 253
- S7, 57–63
- sampling, diagnostic implications, 1
- SCFR (stem cell factor receptor), 128–133
- Schäfer's fixative, fixation time and implications, 4
- sectioning, diagnostic implications, 5
- segmented neutrophils, CD16 in, **55**
- serous atrophy, CD34 in, **93**
- sinusoidal endothelial cells
 CD4 in, **25**
 CD99 in, **125**
- small B-cell lymphoproliferative diseases
 Bcl-2 in, **227**
 flow cytometry diagnostic role, 3
- smooth muscle actin
 localization in diagnosis, 2
 in pericytes; contrasted with desmin **217, 218**
- SPI1, 185–190
- staining
 of megakaryocytes for von Willebrand factor, **174, 175**
 of PU.1 in extracellular spaces, **187**

stem cell factor receptor, 128–133
 stromal bone marrow cells, CD9 in, **38**
 stromal cell dendritic extensions, CD10 in, **38, 39**
 stromal cells
 actin association with, **217**
 CD16 in, **56**
 CD99 in, **127**
 CD138 in, **138**
 S-100 protein in, **219**
 vascular cell adhesion molecule in, **220**
 stromal dendritic cells
 CD10 positivity, **42**
 CD14 in, **45, 46**
 CD56 in, **106, 107**
 stromal induction, of CD10 positivity, **42**
 stromal markers, 213–221
 Surgipath decalcifier, decalcification time and processing implications, 5
 syndecan-1, 134–139
 systemic lupus erythematosus, CD20 in, **59**
 systemic mastocytosis
 CD25 in, **77**
 CD61 in, **111**
 mast cell tryptase in, **162–164**
 von Willebrand factor in, **177**

T

T cells
 activated, CD3 in, **18**
 benign, CD5 in with hairy cell leukemia, **30**
 interstitial, CD8 in, **33**
 reactive, CD3 in, **18**
 T lymphocytes in normal bone marrow, CD4 in, **24–25**
 T lymphocytosis, TIA-1 (T-cell intracellular antigen-1) in, **211**
 T1, 27–30
 T11, 16–17
 T200, 97–103
 T3, 17–24
 TAG72, metastatic tumor diagnostic considerations, **250**
 T-cell intracellular antigen-1 (TIA-1)
 localization in diagnosis, 2
 in peripheral T-cell lymphoma, **212**
 recommended panel applications, 253
 in refractory anemia with excess blasts, **211**
 in T-cell large granular lymphocytic leukemia, **213**
 T-cell large granular lymphocytic leukemia
 CD8 in, **35**
 CD57 in, **109**
 TIA-1 vs granzyme B diagnosis, **213**
 T-cell neoplasms, recommended panels, 253
 TdT: See terminal deoxynucleotidyltransferase.
 temperature, tissue processing considerations, 3
 terminal deoxynucleotidyltransferase (TdT), 167–173
 in acute bilineal leukemia, **172**
 in acute biphenotypic leukemia, **171**

acute leukemia diagnostic considerations with acute bilineal and biphenotypic leukemias, **246**
 acute leukemia diagnostic considerations with acute myeloid leukemia, **242**
 acute leukemia diagnostic considerations with acute myelomonocytic leukemia, **241**
 in acute leukemia, undifferentiated, **173**
 in acute lymphoblastic leukemia, **168**
 in acute myeloid leukemia, 171, **172**
 in acute myelomonocytic leukemia, **173**
 in acute promyelocytic leukemia, **172**
 in classical Hodgkin lymphoma, **167**
 localization in diagnosis, 2
 terminal deoxynucleotidyltransferase (TdT), around lymphoid aggregates, **169**
 in normal bone marrow, **167–169**
 vs Pax-5 in non-neoplastic hematopoiesis, **179**
 positive cell association with adipocytes, **168**
 in precursor B-cell lymphoblastic leukemia, **169–171**
 recommended panel applications, 253
 thin tissue sections, hemoglobin A in, **159**
 thrombocytopenia with no definite bone pathology, CD1a in, **13**
 thrombocytosis, von Willebrand factor in, **177**
 TIA-1. See T-cell intracellular antigen-1.
 time of day, tissue processing considerations, 3
 timing, of decalcification in tissue processing, 5
 tissue processing, for diagnosis, 3
 Tp41, 31–32
 Tp67, 27–30
 transformed essential thrombocythemia, CD45RA in, **99**
 TRAP, 224–225
 biopsy sample with AZF fixative, **9**
 in hairy cell leukemia, **225**
 localization in diagnosis, 2
 in normal bone marrow, **224**
 recommended panel applications, 253
 trilinear dyshematopoiesis, CD61 in myelodysplastic syndrome and acute panmyelosis, **111**
 tungsten carbide knives, for sectioning, diagnostic implications, 5
 turnaround time
 diagnostic implications, 6
 implications for decalcification in tissue processing, 5

U

U21B31, 194–199
 undifferentiated acute leukemia
 acute leukemia diagnostic considerations with CD2 negativity, **244**
 acute leukemia diagnostic considerations with Ki-67, **245**
 CD4 in, **56**
 CD10 stromal induction in, **42**
 CD16 in, 56 (illus.), **57**
 CD68 vs CD16 in, **57**
 PU.1 in, **187**
 terminal deoxynucleotidyltransferase (TdT) in, **173**

V

- vascular cell adhesion molecule, in normal marrow, endothelial cells, and dendritic cells, **220**
- vascular smooth muscle, CD9 in, **36**
- VCAM-1 (vascular cell adhesion molecule), in normal marrow, endothelial cells, and dendritic cells, **220**
- vimentin
 - in acute erythroid leukemia, **215**
 - acute leukemia diagnostic considerations with megakaryoblastic leukemia, **243**
 - acute leukemia diagnostic considerations with undifferentiated acute leukemia, **244**
 - in acute myeloid leukemia, **215–216**
 - in B cells (lymph node), **215**
 - in hemophagocytic syndrome, **216**
 - localization in diagnosis, **2**
 - metastatic tumor diagnostic considerations, **251**
 - metastatic tumor diagnostic considerations, **252**
 - in myeloid hypoplasia, **215–216**
 - in normal bone marrow, **214**
 - in refractory anemia with myeloid hyperplasia, **216**
- von Willebrand factor, 174–178
 - acute leukemia diagnostic considerations with acute biphenotypic leukemia, **246**
 - in acute megakaryoblastic leukemia, 177, **178**
 - in acute promyelocytic leukemia, **176**

- in anemia, **175**
- vs CD31 in myelodysplastic syndrome, **82**
- CD61 expression contrasted, **110**
- in dysplastic megakaryocytes, **176**
- in endothelial cells, **175**
- Golgi-type concentration in dysplastic megakaryocytes, **176**
- localization in diagnosis, **2**
- megakaryocyte staining for, 174, **175**
- in myelodysplastic syndrome, **177**
- in normal bone marrow, **174**
- in precursor B-cell lymphoblastic leukemia, **176**
- recommended panel applications, 253
- staining for, 174, **175**
- in systemic mastocytosis, **177**
- in thrombocytosis, **177**

W

W3/25, 24–26

Z

- ZAP70, recommended panel applications, 253
- Zenker fixative, fixation time and implications, **4**
- zinc finger protein 51, 201–203